Heidelberg, 05.10.2021. On Friday October 1, BioRN has been able to welcome its members back on site for the usual Annual Conference.
“I am every time amazed about our network: so many exceptional people, so much exceptional science, so many new connections. All in our neighbourhood!” said Gitte Neubauer (Chair of BioRN Executive Board and Head of Cellzome) during the opening speech.
With the title “Novel Therapeutics: Biotechnology leading the way into the future”, the conference featured some of the biotechnology-driven new therapeutical approaches and partnership models for successful drug development.
The scientific track was opened with the keynote of Holger Kissel (Vice President Business Alliances, BioNTech SE). He gave insights on how breakthrough technologies in life sciences have enabled innovative concepts to address the immunobiology of cancer at its core. He focused on BioNTech’s approach towards individualized cancer therapy.
Recent discoveries for innovative approaches were featured during the sessions, including gene therapy, PROTACs (Protein Targeting Chimeras), proximity-based agents, stimulation of immune surveillance of solid cancers or microbiota contributions to drug metabolism (see Conference Program).
To bring these solutions to the patients, collaboration among industry, academia, regulatory, clinician and patient communities, as well as ad hoc funding and investment frameworks are essential.